Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Inovio Pharmaceuticals, Inc.

INO

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Last trade $1.60
Day change +$0.20 (+14.29%)
Day range $1.38 – $1.63
Volume 12,022,389
Market cap $262M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$262.23M
Price / earnings
—
Price / book
-7.73×
Price / sales
877.31×
EV / sales
720.2×
EV / EBITDA
-2.82×

Profitability

Earnings per share
-$0.38
Return on assets
-118.29%
Return on equity
209.7%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
0.57×
Quick ratio
0.57×
Cash ratio
0.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$74.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$298.9K$0$0$0$0$0$65.34K$116.99K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$298.9K$0$0$0$0$0$65.34K$116.99K
Selling, general and administrative$9.21M$7.8M$7.88M$7.22M$7.88M$8.56M$9.02M$7.6M
Research and development$10.62M$10.83M$14.07M$10.26M$13.33M$14.52M$16.09M$12.89M
Total operating expenses$19.82M$18.62M$21.95M$17.48M$21.21M$23.08M$25.12M$20.49M
Operating income-$19.52M-$18.62M-$21.95M-$17.48M-$21.21M-$23.08M-$25.05M-$20.37M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$49.2M-$6.01M-$19.68M$3.76M-$45.5M-$23.52M-$19.69M-$19.38M
Income taxes$0$0$0$0$0$0$0$0
Net income-$49.2M-$6.01M-$19.68M$3.76M-$45.5M-$23.52M-$19.69M-$19.38M
Net income attributable to common shareholders-$49.2M-$6.01M-$19.68M$3.76M-$45.5M-$23.52M-$19.69M-$19.38M
EBITDA-$19.2M-$18.3M-$21.63M-$17.14M-$20.86M-$22.73M-$24.68M-$19.95M
Basic earnings per share-$0.50-$0.07-$0.28$0.06-$0.87-$0.61-$0.51-$0.65
Diluted earnings per share-$0.50-$0.07-$0.28$0.06-$0.87-$0.61-$0.51-$0.65

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

PGEN Q3 Earnings Call Highlights Launch Momentum and Competition

Precigen (PGEN) reported Q3 2026 revenues of $74.15M, slightly missing consensus estimates, with PAPZIMEOS generating $72.9M in net revenue, up 37% sequentially. The company treated over 500 patients and achieved positive operating cash flow of $11.9M. Management emphasized the therapy's 51% complete response rate and competitive advantages while preparing for upcoming competition from Inovio. The company is pursuing redosing trials, pediatric development, and international expansion opportunities.

Zacks Investment Research

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Precigen is set to report Q3 2026 earnings on Nov. 4 with expected revenues of $75.4 million and EPS of 9 cents. The company's sole marketed drug Papzimeos has shown strong sales momentum, but faces new competitive pressure following FDA approval of Inovio's Voceryq for the same indication (RRP). Precigen's stock fell ~20% following the competitive approval. The company's earnings surprise model does not predict a beat this quarter.

Zacks Investment Research

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer

Pfizer announced FDA approval of Tukysa in combination with Roche's Herceptin and Perjeta for frontline maintenance treatment of HER2-positive breast cancer. The phase III HER2CLIMB-05 study showed Tukysa reduced progression or death risk by 35.9%, with median progression-free survival of 24.9 months versus 16.3 months for placebo. This approval expands Tukysa's use beyond second-line treatment and provides a chemotherapy-free maintenance option.

Zacks Investment Research

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.

GlobeNewswire Inc.

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 25, 20241-for-12reverse split
Jun 6, 20141-for-4reverse split